Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma
Yuting Sun, Jessica L. Bell, Daniel R. Carter, et al.
Cancer Research (2015) Vol. 75, Iss. 23, pp. 5143-5154
Open Access | Times Cited: 94

Showing 1-25 of 94 citing articles:

MYC protein interactors in gene transcription and cancer
Corey Lourenco, Diana Resetca, Cornelia Redel, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 9, pp. 579-591
Closed Access | Times Cited: 246
A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models
Xufen Yu, Dongxu Li, Jithesh Kottur, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 613
Open Access | Times Cited: 118
Moonlighting with WDR5: A Cellular Multitasker
Alissa D. Guarnaccia, William P. Tansey
Journal of Clinical Medicine (2018) Vol. 7, Iss. 2, pp. 21-21
Open Access | Times Cited: 128
In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer
Alessandro Carugo, Giannicola Genovese, Sahil Seth, et al.
Cell Reports (2016) Vol. 16, Iss. 1, pp. 133-147
Open Access | Times Cited: 125
Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance
Lance R. Thomas, Clare M. Adams, Jing Wang, et al.
Proceedings of the National Academy of Sciences (2019) Vol. 116, Iss. 50, pp. 25260-25268
Open Access | Times Cited: 96
The roles and regulation of MDM2 and MDMX: it is not just about p53
Alyssa M. Klein, Rafaela Muniz de Queiroz, Divya Venkatesh, et al.
Genes & Development (2021) Vol. 35, Iss. 9-10, pp. 575-601
Open Access | Times Cited: 96
The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review
Hope S. Rugo, Ira Jacobs, Shikhar Sharma, et al.
Advances in Therapy (2020) Vol. 37, Iss. 7, pp. 3059-3082
Open Access | Times Cited: 87
The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35
Pei Y. Liu, Andrew E. Tee, Giorgio Milazzo, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 83
LncRNA ANRIL acts as a modular scaffold of WDR5 and HDAC3 complexes and promotes alteration of the vascular smooth muscle cell phenotype
Chengxin Zhang, Shangqing Ge, Wenhui Gong, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 6
Open Access | Times Cited: 75
Targeting MYCN in Pediatric and Adult Cancers
Zhihui Liu, Samuel S. Chen, Saki Clarke, et al.
Frontiers in Oncology (2021) Vol. 10
Open Access | Times Cited: 67
Design, Synthesis, and Evaluation of WD-Repeat-Containing Protein 5 (WDR5) Degraders
Anja Dölle, Bikash Adhikari, Andreas Krämer, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 15, pp. 10682-10710
Open Access | Times Cited: 64
Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic
Dongxu Li, Xufen Yu, Jithesh Kottur, et al.
Oncogene (2022) Vol. 41, Iss. 24, pp. 3328-3340
Open Access | Times Cited: 40
Discovery of Potent Small-Molecule Inhibitors of WDR5-MYC Interaction
Jian Ding, Guo Li, Hejun Liu, et al.
ACS Chemical Biology (2023) Vol. 18, Iss. 1, pp. 34-40
Closed Access | Times Cited: 25
Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1)
Matthäus Getlik, David Smil, Carlos Zepeda‐Velázquez, et al.
Journal of Medicinal Chemistry (2016) Vol. 59, Iss. 6, pp. 2478-2496
Closed Access | Times Cited: 78
The Histone H3 Lysine 4 Presenter WDR5 as an Oncogenic Protein and Novel Epigenetic Target in Cancer
Kebin Lu, Tao He, Xiaomin Si, et al.
Frontiers in Oncology (2018) Vol. 8
Open Access | Times Cited: 73
The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription
Matthew Wong, Andrew E. Tee, Giorgio Milazzo, et al.
Cancer Research (2017) Vol. 77, Iss. 9, pp. 2522-2533
Open Access | Times Cited: 72
WDR5 high expression and its effect on tumorigenesis in leukemia
Zheng Ge, E Song, Yuka Imamura Kawasawa, et al.
Oncotarget (2016) Vol. 7, Iss. 25, pp. 37740-37754
Open Access | Times Cited: 65
Discovery of Potent 2-Aryl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazoles as WDR5-WIN-Site Inhibitors Using Fragment-Based Methods and Structure-Based Design
Feng Wang, Kyu Ok Jeon, James M. Salovich, et al.
Journal of Medicinal Chemistry (2018) Vol. 61, Iss. 13, pp. 5623-5642
Open Access | Times Cited: 64
WDR5 is a conserved regulator of protein synthesis gene expression
Audra F. Bryan, Jing Wang, Gregory C. Howard, et al.
Nucleic Acids Research (2020) Vol. 48, Iss. 6, pp. 2924-2941
Open Access | Times Cited: 57
Discovery of Potent and Selective WDR5 Proteolysis Targeting Chimeras as Potential Therapeutics for Pancreatic Cancer
Xufen Yu, Dongxu Li, Jithesh Kottur, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 23, pp. 16168-16186
Closed Access | Times Cited: 19
Network Modeling of microRNA–mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN
Chi Yan Ooi, Daniel R. Carter, Bing Liu, et al.
Cancer Research (2018) Vol. 78, Iss. 12, pp. 3122-3134
Open Access | Times Cited: 59
MYC in Germinal Center‐derived lymphomas: Mechanisms and therapeutic opportunities
Andrea Bisso, Arianna Sabò, Bruno Amati
Immunological Reviews (2019) Vol. 288, Iss. 1, pp. 178-197
Closed Access | Times Cited: 48
Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core
Jianhua Tian, Kevin B. Teuscher, Erin R. Aho, et al.
Journal of Medicinal Chemistry (2019) Vol. 63, Iss. 2, pp. 656-675
Open Access | Times Cited: 48
The complex activities of the SET1/MLL complex core subunits in development and disease
Hao Jiang
Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms (2020) Vol. 1863, Iss. 7, pp. 194560-194560
Open Access | Times Cited: 43
Targeting WD Repeat-Containing Protein 5 (WDR5): A Medicinal Chemistry Perspective
Xin Chen, Junjie Xu, Xianghan Wang, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 15, pp. 10537-10556
Closed Access | Times Cited: 38
Page 1 - Next Page

Scroll to top